SÃ¸ren M Bentzen

List of Publications by Year
in descending order

533 papers	34,155 citations	2802 94 h-index	4991 167 g-index
543 all docs	543 docs citations	543 times ranked	23564 citing authors

#	Article	IF	Citations
1	Use of Normal Tissue Complication Probability Models in the Clinic. International Journal of Radiation Oncology Biology Physics, 2010, 76, S10-S19.	0.8	1,376
2	The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, The, 2008, 371, 1098-1107.	13.7	1,030
3	Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. International Journal of Radiation Oncology Biology Physics, 2010, 76, S3-S9.	0.8	879
4	Radiation Doseâ€"Volume Effects in the Lung. International Journal of Radiation Oncology Biology Physics, 2010, 76, S70-S76.	0.8	878
5	Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nature Reviews Cancer, 2006, 6, 702-713.	28.4	868
6	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 2005, 77, 18-24.	0.6	867
7	Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology, 2013, 15, 1429-1437.	1.2	746
8	Radiation oncology in the era of precision medicine. Nature Reviews Cancer, 2016, 16, 234-249.	28.4	636
9	Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet, The, 1995, 345, 540-543.	13.7	551
10	Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncology, The, 2006, 7, 467-471.	10.7	520
11	Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiotherapy and Oncology, 2005, 75, 9-17.	0.6	452
12	Time-dose factors in radiotherapy: a review of the human data. Radiotherapy and Oncology, 1990, 19, 219-235.	0.6	389
13	Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncology, The, 2005, 6, 112-117.	10.7	385
14	Fractionation for Whole Breast Irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. International Journal of Radiation Oncology Biology Physics, 2011, 81, 59-68.	0.8	366
15	Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR in Biomedicine, 2002, 15, 132-142.	2.8	323
16	Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1057-1063.	1.6	301
17	International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiotherapy and Oncology, 2002, 64, 275-280.	0.6	300
18	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function. Journal of Clinical Oncology, 2007, 25, 1260-1266.	1.6	299

#	ARTICLE	IF	CITATIONS
19	Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiotherapy and Oncology, 1998, 47, 233-240.	0.6	284
20	Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Recruited in the CHART Randomized Trial. Journal of Clinical Oncology, 2006, 24, 727-735.	1.6	276
21	PET-CTâ€"Based Auto-Contouring in Nonâ€"Small-Cell Lung Cancer Correlates With Pathology and Reduces Interobserver Variability in the Delineation of the Primary Tumor and Involved Nodal Volumes. International Journal of Radiation Oncology Biology Physics, 2007, 68, 771-778.	0.8	274
22	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. Journal of Clinical Oncology, 2010, 28, 4912-4918.	1.6	264
23	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2008, 71, 64-70.	0.8	259
24	Radiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen. Journal of the National Cancer Institute, 1996, 88, 918-922.	6.3	257
25	Molecular Imagingâ€"Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription. Seminars in Radiation Oncology, 2011, 21, 101-110.	2.2	252
26	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiotherapy and Oncology, 2016, 120, 441-446.	0.6	252
27	Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial. Journal of Clinical Oncology, 2005, 23, 5560-5567.	1.6	250
28	Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 74-80.	0.8	219
29	Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4562-4568.	1.6	217
30	Clinical radiobiology of malignant melanoma. Radiotherapy and Oncology, 1989, 16, 169-182.	0.6	216
31	Selective mediastinal node irradiation based on FDG-PET scan data in patients with nonâ€"small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 988-994.	0.8	202
32	Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiotherapy and Oncology, 2005, 75, 355-365.	0.6	202
33	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncology, The, 2012, 13, 65-77.	10.7	202
34	Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. International Journal of Hyperthermia, 1996, 12, 3-20.	2.5	201
35	Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiotherapy and Oncology, 1989, 15, 267-274.	0.6	196
36	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers. Annals of Internal Medicine, 2017, 167, 311.	3.9	192

#	ARTICLE	IF	CITATIONS
37	Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Seminars in Radiation Oncology, 1994, 4, 68-80.	2.2	190
38	A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta OncolÃ³gica, 2012, 51, 975-983.	1.8	190
39	Bioeffect modeling and equieffective dose concepts in radiation oncology â€“ Terminology, quantities and units. Radiotherapy and Oncology, 2012, 105, 266-268.	0.6	185
40	Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 89-94.	0.8	179
41	Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity. Acta OncolÃ³gica, 1994, 33, 383-389.	1.8	177
42	Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, 589-597.	0.8	176
43	Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiotherapy and Oncology, 1991, 20, 159-165.	0.6	172
44	The Lessons of QUANTEC: Recommendations for Reporting and Gathering Data on Doseâ€“Volume Dependencies of Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2010, 76, S155-S160.	0.8	171
45	Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.. Journal of Clinical Oncology, 1996, 14, 1146-1155.	1.6	170
46	Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistryâ€"Initial Observations. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1065-1071.	0.8	169
47	Biologic Basis for Combining Drugs With Radiation. Seminars in Radiation Oncology, 2006, 16, 2-9.	2.2	167
48	Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and Oncology, 2010, 95, 327-331.	0.6	166
49	Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.. Journal of Clinical Oncology, 1997, 15, 3030-3037.	1.6	157
50	Clinical radiobiology of squamous cell carcinoma of the oropharynx. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1197-1206.	0.8	155
51	Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiotherapy and Oncology, 2006, 78, 236-244.	0.6	154
52	Evaluation of Early and Late Toxicities in Chemoradiation Trials. Journal of Clinical Oncology, 2007, 25, 4096-4103.	1.6	154
53	Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiotherapy and Oncology, 1991, 22, 161-166.	0.6	153
54	Doseâ€“effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiotherapy and Oncology, 2016, 118, 160-166.	0.6	153

#	ARTICLE	IF	CITATIONS
55	Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 nonâ€“small-cell lung cancer: A modeling study. International Journal of Radiation Oncology Biology Physics, 2005, 61, 649-655.	0.8	151
56	Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents â€“ A Potential Therapy for Cancer. Cancer Cell, 2016, 30, 637-650.	16.8	151
57	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018, 8, 354-360.	2.1	151
58	Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiotherapy and Oncology, 1996, 40, 101-109.	0.6	149
59	The Î±/Î² ratio for prostate cancer: What is it, really?. Radiotherapy and Oncology, 2005, 76, 1-3.	0.6	149
60	Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1. Radiotherapy and Oncology, 2005, 75, 349.E1-349.E6.	0.6	148
61	Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiotherapy and Oncology, 1998, 46, 5-18.	0.6	145
62	The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials. Journal of Clinical Oncology, 2004, 22, 19-22.	1.6	143
63	Quantifying the position and steepness of radiation dose-response curves. International Journal of Radiation Biology, 1997, 71, 531-542.	1.8	142
64	Hypofractionated Whole-Breast Radiotherapy for Women With Early Breast Cancer: Myths and Realities. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1-9.	0.8	142
65	The predictive value of quantitative computed tomography for vertebral body compressive strength and ash density. Bone, 1989, 10, 465-470.	2.9	141
66	Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1106-1113.	0.8	139
67	Integral radiation dose to normal structures with conformal external beam radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 962-967.	0.8	139
68	Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy and Oncology, 2001, 60, 123-135.	0.6	136
69	Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiotherapy and Oncology, 2005, 77, 5-10.	0.6	135
70	Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4343-4348.	1.6	132
71	Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 198-204.	0.8	130
72	Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nature Clinical Practice Oncology, 2007, 4, 172-180.	4.3	129

#	ARTICLE	IF	CITATIONS
73	Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiotherapy and Oncology, 2002, 65, 9-16.	0.6	128
74	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.6	128
75	Normal tissue effects: reporting and analysis. Seminars in Radiation Oncology, 2003, 13, 189-202.	2.2	127
76	The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiotherapy and Oncology, 1987, 9, 1-11.	0.6	121
77	Evidence for a Positive Correlation betweenin VitroRadiosensitivity of Normal Human Skin Fibroblasts and the Occurrence of Subcutaneous Fibrosis after Radiotherapy. International Journal of Radiation Biology, 1994, 66, 407-412.	1.8	120
78	Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiotherapy and Oncology, 1999, 53, 219-226.	0.6	118
79	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
80	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Clinical Oncology, 2018, 36, 3411-3430.	1.6	118
81	Fractionation Parameters for Human Tissues and Tumors. International Journal of Radiation Biology, 1989, 56, 701-710.	1.8	111
82	Delay in the diagnosis of oral squamous cell carcinoma. Clinical Otolaryngology, 1995, 20, 21-25.	1.2	111
83	Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 1994, 29, 941-952.	0.8	109
84	Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients. Journal of Clinical Oncology, 2001, 19, 3376-3384.	1.6	109
85	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. British Journal of Cancer, 2019, 120, 1003-1006.	6.4	109
86	Radiobiological considerations in the design of clinical trials. Radiotherapy and Oncology, 1994, 32, 1-11.	0.6	107
87	X-ray quantitative computed tomography: The relations to physical properties of proximal tibial trabecular bone specimens. Journal of Biomechanics, 1989, 22, 837-844.	2.1	106
88	Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity. European Journal of Cancer, 1993, 29, 1373-1376.	2.8	104
89	Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiotherapy and Oncology, 2014, 111, 360-365.	0.6	102
90	Improving Normal Tissue Complication Probability Models: The Need to Adopt a â€œData-Poolingâ€• Culture. International Journal of Radiation Oncology Biology Physics, 2010, 76, S151-S154.	0.8	101

#	ARTICLE	IF	CITATIONS
91	Tumor volume and local control probability: Clinical data and radiobiological interpretations. International Journal of Radiation Oncology Biology Physics, 1996, 36, 247-251.	0.8	100
92	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.8	99
93	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98
94	Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. British Journal of Cancer, 1992, 65, 102-107.	6.4	97
95	Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinomaâ€"Patient- and Treatment-Related Risk Factors. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1121-1128.	0.8	95
96	Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta OncolÃ³gica, 2005, 44, 904-912.	1.8	94
97	Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide. Journal of Clinical Oncology, 2006, 24, 45-51.	1.6	94
98	Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. British Journal of Cancer, 2002, 86, 517-523.	6.4	93
99	Randomized controlled trials in health technology assessment: Overkill or overdue?. Radiotherapy and Oncology, 2008, 86, 142-147.	0.6	93
100	Fractionation sensitivity of a functional endpoint: impaired shoulder movement after post-mastectomy radiotherapy. International Journal of Radiation Oncology Biology Physics, 1989, 17, 531-537.	0.8	91
101	Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials. Journal of Clinical Oncology, 2000, 18, 1733-1739.	1.6	90
102	Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and Oncology, 2012, 105, 145-149.	0.6	89
103	Morbidity Related to Axillary Irradiation in the Treatment of Breast Cancer. Acta OncolÃ³gica, 2000, 39, 337-347.	1.8	87
104	Risk factors for radiation-induced hypothyroidism. Cancer, 2011, 117, 5250-5260.	4.1	87
105	Altered fractionation and combined radio-chemotherapy approaches. European Journal of Cancer, 2003, 39, 560-571.	2.8	86
106	Molecular therapy in head and neck oncology. Nature Reviews Clinical Oncology, 2009, 6, 266-277.	27.6	86
107	Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression Analysis. Acta OncolÃ³gica, 1998, 37, 277-284.	1.8	85
108	â€œRadiobiology of Proton Therapyâ€• Results of an international expert workshop. Radiotherapy and Oncology, 2018, 128, 56-67.	0.6	85

#	ARTICLE	IF	CITATIONS
109	Risk Factors for Central Nervous System Involvement in Non-Hodgkins-Lymphoma a multivariate analysis. Acta OncolÃ³gica, 1996, 35, 703-708.	1.8	84
110	Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment â€¦ now!. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1531-1534.	0.8	83
111	Molecular Marker Profiles Predict Locoregional Control of Head and Neck Squamous Cell Carcinoma in a Randomized Trial of Continuous Hyperfractionated Accelerated Radiotherapy. Clinical Cancer Research, 2004, 10, 3745-3754.	7.0	83
112	Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiotherapy and Oncology, 1997, 43, 121-131.	0.6	82
113	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and) Tj ETQq1 1 0.784314 rgBT /Ov	3.7	82
114	An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. International Journal of Radiation Oncology Biology Physics, 2006, 65, 91-99.	0.8	80
115	Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, 973-982.	0.8	80
116	Direct Estimation of Latent Time for Radiation Injury in Late-responding Normal Tissues: Gut, Lung, and Spinal Cord. International Journal of Radiation Biology, 1989, 55, 27-43.	1.8	77
117	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Physics in Medicine and Biology, 2007, 52, 499-513.	3.0	77
118	Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512). International Journal of Radiation Oncology Biology Physics, 2014, 89, 958-963.	0.8	77
119	Early and Late Normal-tissue Injury after Postmastectomy Radiotherapy Alone or Combined with Chemotherapy. International Journal of Radiation Biology, 1989, 56, 711-715.	1.8	76
120	Cancer Risk from Bone Morphogenetic Protein Exposure in Spinal Arthrodesis. Journal of Bone and Joint Surgery - Series A, 2014, 96, 1417-1422.	3.0	75
121	Prognostic factors in osteosarcomas. A regression analysis. Cancer, 1988, 62, 194-202.	4.1	74
122	Assessment of Machine Learning vs Standard Prediction Rules for Predicting Hospital Readmissions. JAMA Network Open, 2019, 2, e190348.	5.9	71
123	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	6.3	71
124	National Audit of the Management and Outcome of Carcinoma of the Cervix Treated with Radiotherapy in 1993. Clinical Oncology, 2000, 12, 347-353.	1.4	70
125	High-tech in radiation oncology: should there be a ceiling?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 320-330.	0.8	70
126	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1496-1504.	0.8	70

#	ARTICLE	IF	CITATIONS
127	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 766-778.	0.8	70
128	Mechanical strength of tibial trabecular bone evaluated by X-ray computed tomography. Journal of Biomechanics, 1987, 20, 743-752.	2.1	69
129	Some Methodological Problems in Estimating Radiobiological Parameters from Clinical Dataâ€"Alpha/beta Ratios and Electron RBE for Cutaneous Reactions in Patients Treated with Postmastectomy Radiotherapy. Acta OncolÃ³gica, 1988, 27, 105-116.	1.8	69
130	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Physics in Medicine and Biology, 2008, 53, 4153-4167.	3.0	69
131	Biomarkers and Surrogate Endpoints for Normal-Tissue Effects of Radiation Therapy: The Importance of Doseâ€"Volume Effects. International Journal of Radiation Oncology Biology Physics, 2010, 76, S145-S150.	0.8	69
132	Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology, 2012, 14, 882-889.	1.2	69
133	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69
134	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.8	69
135	Reports of Unexpected Late Side Effects of Accelerated Partial Breast Irradiationâ€"Radiobiological Considerations. International Journal of Radiation Oncology Biology Physics, 2010, 77, 969-973.	0.8	68
136	Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiotherapy and Oncology, 1996, 38, 89-101.	0.6	66
137	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiotherapy and Oncology, 2006, 78, 123-130.	0.6	66
138	Radiation Dose Prescription for Nonâ€"Small-Cell Lung Cancer According to Normal Tissue Dose Constraints: An In Silico Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1103-1110.	0.8	66
139	Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study. Technology in Cancer Research and Treatment, 2008, 7, 441-447.	1.9	65
140	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiotherapy and Oncology, 2012, 105, 289-295.	0.6	65
141	Histopathologic, stereologic, epidemiologic, and clinical parameters in the prognostic evaluation of squamous cell carcinoma of the oral cavity. , 1996, 18, 142-152.		63
142	Are We Influencing Outcome in Oropharynx Cancer With Intensity-Modulated Radiotherapy? An Inter-Era Comparison. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1032-1041.	0.8	63
143	Standardized Total Average Toxicity Score: A Scale- and Grade-Independent Measure of Late Radiotherapy Toxicity to Facilitate Pooling of Data From Different Studies. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1065-1074.	0.8	63
144	Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncology, 2014, 10, 2391-2406.	2.4	63

#	ARTICLE	IF	CITATIONS
145	Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. International Journal of Radiation Oncology Biology Physics, 2000, 46, 481-490.	0.8	62
146	An evolutionary-game model of tumourâ€“cell interactions: possible relevance to gene therapy. European Journal of Cancer, 2001, 37, 2116-2120.	2.8	62
147	Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trialsâ€"Report of the NationalÂCancer Institute Work Group on Radiotherapy Quality Assurance. International Journal of Radiation Oncology Biology Physics, 2012, 83, 782-790.	0.8	62
148	Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. Journal of Neuro-Oncology, 2014, 116, 187-193.	2.9	62
149	Locoregional Control of Non-Small Cell Lung Cancer in Relation to Automated Early Assessment of Tumor Regression on Cone Beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 89, 916-923.	0.8	62
150	Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2018, 100, 858-865.	0.8	62
151	Life years lostâ€"comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer, 2012, 118, 5432-5440.	4.1	61
152	Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. Acta OncolÃ³gica, 2014, 53, 605-612.	1.8	61
153	Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2017, 104, 52-57.	2.0	61
154	Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 228-235.	0.8	61
155	Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. European Journal of Cancer, 2000, 36, 615-620.	2.8	60
156	NCIâ€“RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. Journal of the National Cancer Institute, 2013, 105, 11-24.	6.3	60
157	Repopulation in radiation oncology: perspectives of clinical research. International Journal of Radiation Biology, 2003, 79, 581-585.	1.8	59
158	STROGAR â€“ STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiotherapy and Oncology, 2014, 110, 182-188.	0.6	59
159	Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology, 1999, 10, 21-27.	1.2	59
160	Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: a graded-response analysis. Radiotherapy and Oncology, 1990, 18, 95-106.	0.6	58
161	Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiotherapy and Oncology, 2005, 77, 227-230.	0.6	58
162	Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Doseâ€“Volume Response Relationships for Paediatric Cancer Patients. Clinical Oncology, 2019, 31, 199-207.	1.4	58

#	ARTICLE	IF	CITATIONS
163	Steepness of the Clinical Doseâ€“control Curve and Variation in thein VitroRadiosensitivity of Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Biology, 1992, 61, 417-423.	1.8	57
164	On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Physics in Medicine and Biology, 2009, 54, 1483-1501.	3.0	57
165	Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart. Clinical Oncology, 2013, 25, 147-152.	1.4	57
166	A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis?. British Journal of Cancer, 1988, 58, 195-201.	6.4	56
167	Differentiation state of skin fibroblast cultures versus risk of subcutaneous fibrosis after radiotherapy. Radiotherapy and Oncology, 1998, 47, 263-269.	0.6	56
168	Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience. Head and Neck, 2010, 32, 599-606.	2.0	56
169	Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1069-1072.	0.8	55
170	Quantitative Clinical Radiobiology. Acta OncolÃ³gica, 1993, 32, 259-275.	1.8	55
171	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiotherapy and Oncology, 2016, 120, 76-80.	0.6	55
172	Phase I Trial of Pelvic Nodal Dose Escalation With Hypofractionated IMRT for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 184-190.	0.8	54
173	Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: Normal tissue complication probability modeling with latent time correction. Radiotherapy and Oncology, 2013, 109, 317-322.	0.6	54
174	Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxyâ€terminal telopeptide of type I collagen (ICTP). British Journal of Haematology, 1997, 96, 103-110.	2.5	53
175	Immune effector cellâ€“associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology, 2021, 23, 112-121.	1.2	53
176	ERRATUM. Acta OncolÃ³gica, 2006, 45, 110-110.	1.8	52
177	Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 172-187.	0.8	52
178	Does Variation in thein VitroCellular Radiosensitivity Explain the Shallow Clinical Doseâ€”control Curve for Malignant Melanoma?. International Journal of Radiation Biology, 1990, 57, 117-126.	1.8	51
179	From CHART to CHARTWEL in Non-small Cell Lung Cancer: Clinical Radiobiological Modelling of the Expected Change in Outcome. Clinical Oncology, 2002, 14, 372-381.	1.4	51
180	Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. International Journal of Radiation Oncology Biology Physics, 2003, 55, 568-575.	0.8	50

#	Article	IF	Citations
181	bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. International Journal of Radiation Oncology Biology Physics, 2001, 49, 435-441.	0.8	49
182	Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nuclear Medicine and Biology, 2011, 38, 771-780.	0.6	49
183	Evaluation of the spatial resolution of a CT scanner by direct analysis of the edge response function. Medical Physics, 1983, 10, 579-581.	3.0	48
184	Prognostic Value of Pretreatment Factors in Patients with Locally Advanced Carcinoma of the Uterine Cervix Treated by Radiotherapy Alone. Acta OncolÃ³gica, 1995, 34, 787-795.	1.8	48
185	Doubly Excited States in Be III. Physica Scripta, 1980, 22, 119-122.	2.5	47
186	Early Morbidity after Radiotherapy with or without Chemotherapy in Advanced Head and Neck Cancer. Strahlentherapie Und Onkologie, 2003, 179, 390-395.	2.0	47
187	Linear Accelerator Radiosurgery for Trigeminal Neuralgia. Neurosurgery, 2005, 57, 1193-1200.	1.1	47
188	Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1084-1090.	0.8	47
189	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. International Journal of Radiation Oncology Biology Physics, 2020, 108, 379-389.	0.8	47
190	Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiotherapy and Oncology, 2004, 72, 275-282.	0.6	46
191	Randomized, Doubleâ€Blinded, Placeboâ€Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Shortâ€Term Androgen Deprivation Therapy: Results of RTOG 0215. Journal of Sexual Medicine, 2011, 8, 1228-1238.	0.6	46
192	Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. International Journal of Radiation Oncology Biology Physics, 2014, 90, 110-118.	0.8	46
193	Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. Aids, 2017, 31, 857-862.	2.2	46
194	Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 754-761.	0.8	46
195	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiotherapy and Oncology, 1998, 46, 127-130.	0.6	45
196	From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. Seminars in Radiation Oncology, 2008, 18, 75-88.	2.2	45
197	Time evolution of regional CT density changes in normal lung after IMRT for NSCLC. Radiotherapy and Oncology, 2013, 109, 89-94.	0.6	45
198	A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiotherapy and Oncology, 1994, 30, 227-230.	0.6	44

#	ARTICLE	IF	CITATIONS
199	Radiation dose response of normal lung assessed by Cone Beam CT â€“ A potential tool for biologically adaptive radiation therapy. Radiotherapy and Oncology, 2011, 100, 351-355.	0.6	44
200	Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiotherapy and Oncology, 1993, 28, 148-156.	0.6	43
201	TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLY. Journal of Urology, 1998, 159, 1609-1614.	0.4	43
202	Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiotherapy and Oncology, 1999, 53, 93-98.	0.6	43
203	Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Annals of Oncology, 2007, 18, 909-916.	1.2	43
204	Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial. Radiotherapy and Oncology, 2009, 91, 120-125.	0.6	43
205	Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. British Journal of Cancer, 1998, 78, 96-99.	6.4	42
206	Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. International Journal of Hyperthermia, 2009, 25, 323-334.	2.5	42
207	Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta OncolÃ³gica, 2010, 49, 964-971.	1.8	42
208	HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 132-138.	0.8	41
209	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 805-814.	4.2	41
210	Fibroblast Differentiation in Subcutaneous Fibrosis after Postmastectomy Radiotherapy. Acta OncolÃ³gica, 2000, 39, 383-388.	1.8	40
211	Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. American Heart Journal, 2017, 192, 48-56.	2.7	38
212	NK cell expression of Tim-3: First impressions matter. Immunobiology, 2019, 224, 362-370.	1.9	38
213	Density changes at the proximal tibia after medial meniscectomy. Journal of Orthopaedic Research, 1989, 7, 744-753.	2.3	37
214	Prognostic Factors in Papillary and Follicular Thyroid Carcinomas. Laryngoscope, 1998, 108, 243-249.	2.0	37
215	A New Method for Synthesizing Radiation Doseâ€“Response Data From Multiple Trials Applied to Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1066-1071.	0.8	37
216	Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 299-304.	0.8	37

#	ARTICLE	IF	CITATIONS
217	Short and Long Term Outcome in a Consecutive Series of 419 Patients with Acute Dialysis-Requiring Renal Failure. Scandinavian Journal of Urology and Nephrology, 1993, 27, 453-462.	1.4	36
218	Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro-Oncology, 2014, 16, 594-602.	1.2	36
219	Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiotherapy and Oncology, 2016, 121, 420-423.	0.6	36
220	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	2.8	36
221	Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2018, 81, 217-222.	2.3	36
222	Time Course of Radiological Lung Density Changes After Postmastectomy Radiotherapy. Acta OncolÃ³gica, 2000, 39, 181-187.	1.8	35
223	Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiotherapy and Oncology, 2003, 69, 195-200.	0.6	35
224	Blood transfusion and prognosis in Dukes' B and C colorectal cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 457-463.	0.7	34
225	Reporting radiotherapeutic complications in patients with uterine cervical cancer. The importance of latency and classification system. Radiotherapy and Oncology, 1993, 28, 134-141.	0.6	34
226	On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy. Medical Dosimetry, 2010, 35, 297-303.	0.9	34
227	Hypofractionated Radiotherapy for Breast Cancer. New England Journal of Medicine, 2010, 362, 1843-1844.	27.0	34
228	Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2012, 188, 671-676.	2.0	34
229	Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 433-445.	0.8	34
230	The translational research chain: is it delivering the goods?. International Journal of Radiation Oncology Biology Physics, 2001, 49, 345-351.	0.8	33
231	Clinical radiation doses for spinal cord: the 1998 international questionnaire. Radiotherapy and Oncology, 2000, 55, 295-300.	0.6	32
232	Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping. International Journal of Radiation Oncology Biology Physics, 2011, 80, 893-899.	0.8	32
233	Risk of Cerebrovascular Events in Elderly Patients After Radiation Therapy Versus Surgery for Early-Stage Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 290-296.	0.8	32
234	Radiotherapy for breast cancer, the TARGIT-A trial. Lancet, The, 2014, 383, 1716-1717.	13.7	32

#	ARTICLE	IF	CITATIONS
235	Spectroscopy of the uranium ion using collinear fast-beamâ€"cw-dye-laser modulation spectroscopy. Transition energies and excited-state lifetimes. Physical Review A, 1981, 24, 2523-2531.	2.5	31
236	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 1998, 46, 147-155.	0.6	31
237	Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1405-1409.	0.8	31
238	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Technology in Cancer Research and Treatment, 2009, 8, 149-158.	1.9	31
239	Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. Clinical Pharmacology and Therapeutics, 2018, 104, 390-400.	4.7	31
240	Remodeling of the tibial plateau after knee replacement: CT bone densitometry. Acta Orthopaedica, 1988, 59, 567-573.	1.4	30
241	Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. European Journal of Cancer & Clinical Oncology, 1988, 24, 377-384.	0.7	30
242	Loss of Reirradiation Tolerance in the Kidney with Increasing Time after Single or Fractionated Partial Tolerance Doses. International Journal of Radiation Biology, 1994, 66, 169-179.	1.8	30
243	A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning. Radiotherapy and Oncology, 2006, 79, 115-121.	0.6	30
244	Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database. Annals of Surgical Oncology, 2017, 24, 2907-2914.	1.5	30
245	Prognostic factor studies in oncology: osteosarcoma as a clinical example. International Journal of Radiation Oncology Biology Physics, 2001, 49, 513-518.	0.8	29
246	Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treatment and Research, 2008, 139, 41-62.	0.5	29
247	New Options in Direct Analysis of Doseâ€"response Data. International Journal of Radiation Biology, 1990, 57, 221-225.	1.8	28
248	Conducting radiogenomic research â€" Do not forget careful consideration of the clinical data. Radiotherapy and Oncology, 2012, 105, 337-340.	0.6	28
249	Doubly excited quartet states in Be II. Journal of Physics B: Atomic and Molecular Physics, 1981, 14, 3435-3443.	1.6	27
250	Increasing Toxicity in Nonoperative Head and Neck Cancer Treatment: Investigations and Interventions. International Journal of Radiation Oncology Biology Physics, 2007, 69, S79-S82.	0.8	26
251	Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta OncolÃ³gica, 2010, 49, 1052-1057.	1.8	26
252	Failure-probability driven dose painting. Medical Physics, 2013, 40, 081717.	3.0	26

#	ARTICLE	IF	CITATIONS
253	Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta OncolÃ³gica, 2015, 54, 1408-1415.	1.8	26
254	Multiple biomarker tissue microarrays: bioinformatics and practical approaches. Cancer and Metastasis Reviews, 2008, 27, 481-494.	5.9	25
255	Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta OncolÃ³gica, 2011, 50, 772-776.	1.8	25
256	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta OncolÃ³gica, 2015, 54, 179-186.	1.8	25
257	Late functional response of mouse urinary bladder to fractionated X-irradiation. International Journal of Radiation Biology, 1999, 75, 1307-1315.	1.8	24
258	UPDATED DATA FOR CHART IN NSCLC: FURTHER ANALYSES. Radiotherapy and Oncology, 2000, 55, 86-87.	0.6	24
259	Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis. Stem Cells Translational Medicine, 2015, 4, 878-886.	3.3	24
260	External validation of a normal tissue complication probability model for radiation-induced hypothyroidism in an independent cohort. Acta OncolÃ³gica, 2015, 54, 1301-1309.	1.8	24
261	Radiosensitivity of normal fibroblasts from breast cancer patients assessed by the micronucleus and colony assays. International Journal of Radiation Biology, 1998, 73, 671-678.	1.8	23
262	Overall treatment time and tumor control dose for head and neck tumors: The dog leg revisited. Radiotherapy and Oncology, 1992, 25, 143-144.	0.6	22
263	Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. European Journal of Cancer, 2004, 40, 2734-2741.	2.8	22
264	Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. BMC Cancer, 2018, 18, 1026.	2.6	22
265	Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. Head and Neck, 2019, 41, 2514-2524.	2.0	22
266	Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidityâ€"Applied in the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2020, 106, 300-309.	0.8	22
267	Clinical Radiobiology and Normal-Tissue Morbidity after Breast Cancer Treatment. Advances in Radiation Biology, 1994, , 25-51.	0.4	21
268	Plasma tetranectin and colorectal cancer. European Journal of Cancer, 1995, 31, 888-894.	2.8	21
269	Fractionated radiotherapy for metastatic bone pain: evidence-based medicine or...?. International Journal of Radiation Oncology Biology Physics, 2000, 46, 681-682.	0.8	21
270	A systematic methodology review of phase I radiation dose escalation trials. Radiotherapy and Oncology, 2010, 95, 135-141.	0.6	21

#	ARTICLE	IF	CITATIONS
271	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. Journal of Neuro-Oncology, 2017, 134, 331-338.	2.9	21
272	Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. Radiotherapy and Oncology, 1995, 37, 87-99.	0.6	20
273	Steepness of the dose-response curve as a function of volume in an experimental tumor irradiated under ambient or hypoxic conditions. International Journal of Radiation Oncology Biology Physics, 1997, 39, 797-802.	0.8	20
274	Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with ¹²³I-MIBG. Journal of Nuclear Medicine, 2015, 56, 52S-58S.	5.0	20
275	Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. Oral Oncology, 2018, 86, 132-140.	1.5	20
276	Experimental investigation of doubly excited states in Be II. Physical Review A, 1982, 26, 2639-2642.	2.5	19
277	Fractionation sensitivity and latency of late radiation injury to the mouse urinary bladder. Radiotherapy and Oncology, 1992, 25, 301-307.	0.6	19
278	Modelling of serial carcinoembryonic antigen changes in colorectal cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 751-755.	1.2	19
279	Radiotherapy for Bone Metastases. Clinical Oncology, 2001, 13, 88-90.	1.4	19
280	Molecular Imaging Biomarkers of Resistance to Radiation Therapy for Spontaneous Nasal Tumors in Canines. International Journal of Radiation Oncology Biology Physics, 2015, 91, 787-795.	0.8	19
281	New identifications of doubly excited quartet states in Be II. Journal of Physics B: Atomic and Molecular Physics, 1982, 15, L71-L74.	1.6	18
282	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: An exploratory study. Radiotherapy and Oncology, 2012, 105, 41-48.	0.6	18
283	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. Acta OncolÃ³gica, 2014, 53, 462-470.	1.8	18
284	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1274-1281.	2.0	18
285	Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse. Scientific Reports, 2016, 6, 36579.	3.3	18
286	Lifetime measurements in singly ionized erbium using fast-beam laser-modulation spectroscopy. Journal of the Optical Society of America, 1982, 72, 1210.	1.2	17
287	Incidence and latency of radiation reactions. Radiotherapy and Oncology, 1989, 14, 261-262.	0.6	17
288	Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo. British Journal of Cancer, 1990, 61, 61-64.	6.4	17

#	ARTICLE	IF	CITATIONS
289	Influence of sampling time on assessment of potential doubling time. Cytometry, 1994, 16, 144-151.	1.8	17
290	Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. Journal of Autoimmunity, 2017, 84, 97-108.	6.5	17
291	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. International Journal of Radiation Oncology Biology Physics, 2019, 105, 957-967.	0.8	17
292	Problems related to lifetime measurements in complex atoms using beam-foil and fast-beam/laser spectroscopy. Nuclear Instruments & Methods in Physics Research, 1982, 202, 139-145.	0.9	16
293	Repopulation in the SCCVII squamous cell carcinoma assessed by an in vivo-in vitro excision assay. Radiotherapy and Oncology, 1996, 39, 137-144.	0.6	16
294	The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO2 and radiation response in an experimental tumour model. British Journal of Cancer, 1997, 76, 1432-1439.	6.4	16
295	In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. British Journal of Cancer, 1999, 79, 1074-1084.	6.4	16
296	A user's guide to evidence-based oncology. European Journal of Cancer, Supplement, 2003, 1, 77-91.	2.2	16
297	Comparison of Radiation-Induced Normal Lung Tissue Density Changes for Patients From Multiple Institutions Receiving Conventional or Hypofractionated Treatments. International Journal of Radiation Oncology Biology Physics, 2014, 89, 626-632.	0.8	16
298	Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (â‰¥60â€‰Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. Advances in Radiation Oncology, 2017, 2, 259-269.	1.2	16
299	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 559-567.	1.1	16
300	Harnessing data science to advance radiation oncology. Molecular Oncology, 2020, 14, 1514-1528.	4.6	16
301	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 161-173.	0.8	16
302	Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2022, 28, 1313-1322.	7.0	16
303	Isotherm mapping in hyperthermia using subtraction X-ray computed tomography. Radiotherapy and Oncology, 1984, 2, 255-260.	0.6	15
304	How useful are observational reports in the evaluation of interventions for radiation morbidity?: an analysis of formalin therapy for late radiation proctitis. Radiotherapy and Oncology, 2002, 64, 291-295.	0.6	15
305	Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. European Journal of Cancer, 2006, 42, 363-371.	2.8	15
306	Radiotherapy for head and neck cancer: latest developments and future perspectives. Current Opinion in Oncology, 2006, 18, 240-246.	2.4	15

#	ARTICLE	IF	CITATIONS
307	Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234. International Journal of Radiation Oncology Biology Physics, 2008, 72, S33.	0.8	15
308	Locoregional Recurrence Following Accelerated Partial Breast Irradiation for Early-Stage Invasive Breast Cancer: Significance of Estrogen Receptor Status and Other Pathological Variables. Annals of Surgical Oncology, 2013, 20, 3446-3452.	1.5	15
309	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.6	15
310	Consensus Report From the Miami Liver Proton Therapy Conference. Frontiers in Oncology, 2019, 9, 457.	2.8	15
311	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. Frontiers in Pediatrics, 2021, 9, 774348.	1.9	15
312	Direct Estimation of the Fraction of Hypoxic Cells from Tumour-control Data Obtained under Aerobic and Clamped Conditions. International Journal of Radiation Biology, 1991, 59, 1435-1440.	1.8	14
313	Prophylactic cranial irradiation in limited stage small cell lung cancer: Survival benefit in patients with favourable characteristics. European Journal of Cancer, 1996, 32, 772-778.	2.8	14
314	Late morbidity: the Damocles Sword of radiotherapy?. Radiotherapy and Oncology, 2001, 61, 219-221.	0.6	14
315	Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed. Acta OncolÃ³gica, 2005, 44, 825-828.	1.8	14
316	Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. Radiotherapy and Oncology, 2009, 93, 389-395.	0.6	14
317	Elevation of Prostaglandin E 2 in Lung Cancer Patients with Digital Clubbing. Journal of Thoracic Oncology, 2012, 7, 1877-1878.	1.1	14
318	Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta OncolÃ³gica, 2015, 54, 1416-1422.	1.8	14
319	C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages. International Journal of Molecular Sciences, 2021, 22, 9912.	4.1	14
320	Time factor for tonsillar carcinoma. International Journal of Radiation Oncology Biology Physics, 1995, 33, 755-758.	0.8	13
321	Dose- and Time-Dependent Changes in Gene Expression in Human Glioma Cells after Low Radiation Doses. Radiation Research, 2007, 168, 199-208.	1.5	13
322	Proton beam therapy delivered using pencil beam scanning vs. passive scattering/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09. Clinical and Translational Radiation Oncology, 2019, 19, 80-86.	1.7	13
323	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. British Journal of Cancer, 2020, 123, 46-53.	6.4	13
324	Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. Apmis, 1993, 101, 614-620.	2.0	12

#	ARTICLE	IF	CITATIONS
325	A Feasibility Study of Concomitant Boost Radiotherapy for Patients with Cancer of the Supraglottic Larynx. Acta OncolÃ³gica, 1993, 32, 637-640.	1.8	12
326	Continuous or Split-Course Combined External and Intracavitary Radiotherapy of Locally Advanced Carcinoma of the Uterine Cervix. Acta OncolÃ³gica, 1994, 33, 547-555.	1.8	12
327	Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis. British Journal of Cancer, 2001, 85, 1113-1118.	6.4	12
328	Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes. Acta OncolÃ³gica, 2010, 49, 984-990.	1.8	12
329	Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array. Virology Journal, 2017, 14, 112.	3.4	12
330	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. Journal of Neuro-Oncology, 2018, 140, 341-349.	2.9	12
331	Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients. Clinical Lung Cancer, 2019, 20, 248-257.e4.	2.6	12
332	Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. Cancer Chemotherapy and Pharmacology, 2019, 83, 1105-1112.	2.3	12
333	Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100200.	4.5	12
334	Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	12
335	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2016, 118, 460-464.	0.6	11
336	Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer, 2018, 123, 87-90.	2.0	11
337	Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine, 2020, 9, 536.	2.4	11
338	Radiation dose-painting with protons vs. photons for head-and-neck cancer. Acta OncolÃ³gica, 2020, 59, 525-533.	1.8	11
339	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients â€“ initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
340	Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Frontiers in Immunology, 2021, 12, 596646.	4.8	11
341	Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology. Cancer Treatment and Research, 2008, , 40-61.	0.5	11
342	Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health Technology. International Journal of Radiation Oncology Biology Physics, 2008, 72, 12-14.	0.8	10

#	ARTICLE	IF	CITATIONS
343	Changes in pulmonary function after definitive radiotherapy for NSCLC. Radiotherapy and Oncology, 2015, 117, 23-28.	0.6	10
344	A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. Oral Oncology, 2017, 74, 77-82.	1.5	10
345	Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis. Breast Cancer Research and Treatment, 2017, 165, 445-453.	2.5	10
346	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Advances, 2021, 5, 711-724.	5.2	10
347	Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	10
348	Phase III Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) Versus Cisplatin, Etoposide, Bleomycin and Prednisone (CisEBP) for the Treatment of Advanced Non-Hodgkin's Lymphoma of High Grade Malignancy. Acta OncolÃ³gica, 1990, 29, 995-999.	1.8	9
349	Prediction of radiotherapy response using SF2: Why it may work after all. Radiotherapy and Oncology, 1994, 31, 85-86.	0.6	9
350	Time Evolution of the Number of Functional Murine Eccrine Sweat Glands after Irradiation: A Quantitative Analysis of Experimental Data Using a Model of Proliferative and Functional Organization. International Journal of Radiation Biology, 1995, 67, 565-575.	1.8	9
351	Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, fu et al IJROBP 32:577â€“588; 1995. International Journal of Radiation Oncology Biology Physics, 1996, 34, 523-524.	0.8	9
352	Delay in diagnosis in breast cancer. Lancet, The, 1999, 353, 2155-2156.	13.7	9
353	Influence of plasma glutathione levels on radiation mucositis. International Journal of Radiation Oncology Biology Physics, 2001, 51, 460-464.	0.8	9
354	Late neurological complications after irradiation of malignant tumors of the testis. Acta OncolÃ³gica, 2007, 46, 497-503.	1.8	9
355	Radiation oncology health technology assessmentâ€”the best is the enemy of the good. Nature Clinical Practice Oncology, 2008, 5, 563-563.	4.3	9
356	Prescribing and evaluating target dose in dose-painting treatment plans. Acta OncolÃ³gica, 2014, 53, 1251-1256.	1.8	9
357	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. Acta OncolÃ³gica, 2017, 56, 1562-1570.	1.8	9
358	Implementation of and Early Outcomes From Anal Cancer Screening at a Community-Engaged Health Care Facility Providing Care to Nigerian Men Who Have Sex With Men. Journal of Global Oncology, 2019, 5, 1-11.	0.5	9
359	Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology, 1998, 32, 536-546.	2.9	9
360	Are the results of the St Thomas' trial of post-mastectomy radiotherapy inconsistent with the predictions from the linear-quadratic model?. British Journal of Radiology, 1989, 62, 633-634.	2.2	8

#	ARTICLE	IF	CITATIONS
361	Quantitative assessment of radiation-induced lung changes by computerized optical densitometry of routine chest x-rays. International Journal of Radiation Oncology Biology Physics, 1996, 34, 421-427.	0.8	8
362	Re: Five-Day Oral Etoposide Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy. Journal of the National Cancer Institute, 1997, 89, 1892-1893.	6.3	8
363	Progression rate of radiation damage to the mouse kidney: a quantitative analysis of experimental data using a simple mathematical model of the nephron. International Journal of Radiation Biology, 1997, 72, 461-473.	1.8	8
364	A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncology, 2018, 81, 52-60.	1.5	8
365	Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Nonâ€“small-cell Lung Cancer Treated With Curative Intent. Clinical Lung Cancer, 2020, 21, e130-e141.	2.6	8
366	Targeted Intraoperative Radiotherapy for Early Breast Cancer. JAMA Oncology, 2020, 6, 1636.	7.1	8
367	Biological optimization for mediastinal lymphoma radiotherapy â€“ a preliminary study. Acta OncolÃ³gica, 2020, 59, 879-887.	1.8	8
368	Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis. Oncologist, 2021, 26, 579-587.	3.7	8
369	A 100-Year Nordic Perspective On The Dose-Time Problem In Radiobiology. Acta OncolÃ³gica, 1995, 34, 1031-1040.	1.8	7
370	Sequential or Concurrent Tamoxifen and Radiotherapy: To See or Not to Seeâ€”That Is the Question!. Journal of Clinical Oncology, 2005, 23, 6266-6267.	1.6	7
371	Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. AIDS Research and Human Retroviruses, 2019, 35, 267-275.	1.1	7
372	An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2023, 115, 73-76.	0.8	7
373	A Mathematical Model for Cell Killing by Heat Applied to a C3H Mammary Carcinomain Vivo. International Journal of Radiation Biology, 1993, 64, 113-117.	1.8	6
374	Actual versus ideal treatment time in radiotherapy for head and neck cancer: Catching up with the gaps. International Journal of Radiation Oncology Biology Physics, 1995, 31, 687-688.	0.8	6
375	Lise Meitner and Niels Bohr?A Historical Note. Acta OncolÃ³gica, 2000, 39, 1002-1003.	1.8	6
376	Role of chance in familial aggregation of colorectal cancer. British Journal of Cancer, 2001, 84, 1084-1086.	6.4	6
377	A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose. Theoretical Biology and Medical Modelling, 2007, 4, 25.	2.1	6
378	Does Routine Clinical Practice Reproduce the Outcome of Large Prospective Trials? The Analysis of Institutional Database on Patients with Limited-Disease Small-Cell Lung Cancer. Cancer Investigation, 2014, 32, 1-7.	1.3	6

#	ARTICLE	IF	CITATIONS
379	Clinical outcomes of black vs. non-black patients with locally advanced nonâ€“small cell lung cancer. Lung Cancer, 2017, 114, 44-49.	2.0	6
380	Individualized estimates of overall survival in radiation therapy plan optimization â€" A concept study. Medical Physics, 2018, 45, 5332-5342.	3.0	6
381	Outcome-based multiobjective optimization of lymphoma radiation therapy plans. British Journal of Radiology, 2021, 94, 20210303.	2.2	6
382	MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score. Genes, 2021, 12, 12.	2.4	6
383	Impact of CT-Based Treatment Planning on Radiation Therapy of Carcinoma of the Bladder. Acta Radiologica Oncology, 1984, 23, 199-203.	0.5	5
384	Treatment-Related Morbidity and Hospital League Tables: Experience from a National Audit of Radiotherapy-Induced Morbidity in Cervical Carcinoma. Clinical Oncology, 2002, 14, 40-42.	1.4	5
385	Does a local bystander effect necessitate a revision of TCP models that are based on observed clinical data?. Acta OncolÃ³gica, 2006, 45, 406-411.	1.8	5
386	Radiation Oncology Advances: An Introduction. Cancer Treatment and Research, 2008, 139, 1-4.	0.5	5
387	Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, 422-429.	0.8	5
388	Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients. Frontiers in Oncology, 2013, 3, 318.	2.8	5
389	Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09. Clinical and Translational Radiation Oncology, 2020, 22, 50-54.	1.7	5
390	MOâ€Dâ€M100Jâ€01: Dose Painting With Intensity Modulated Proton Therapy and Intensity Modulated Xâ€Ray Therapy: A Comparison. Medical Physics, 2007, 34, 2522-2523.	3.0	5
391	Identifying Psychosocial Needs of Patients With Cancer Undergoing Curative Radiation Therapy in an Inner-City Academic Center to Address Racial Disparities. International Journal of Radiation Oncology Biology Physics, 2022, 114, 185-194.	0.8	5
392	Evaluation of bladder tumor volume and CT number during radiotherapy: a comment on the paper by Swank-Bordewijk and van Kleffens. International Journal of Radiation Oncology Biology Physics, 1985, 11, 1228-1229.	0.8	4
393	Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide. Radiotherapy and Oncology, 1996, 40, 249-257.	0.6	4
394	Characterization and Radiosensitivity of Fibroblasts Derived from Squamous Cell Carcinomas of the Head and Neck, and the Surrounding Oral Mucosa. Acta OncolÃ³gica, 1998, 37, 697-700.	1.8	4
395	ACCELERATED RADIOTHERAPY VS. CHEMORADIATION IN NON-SMALL CELL LUNG CANCER: QUANTIFYING THE HAZARDS. Radiotherapy and Oncology, 2001, 58, 91-92.	0.6	4
396	Pre-treatment Haemoglobin Concentration in Accelerated and Conventional Radiotherapy for Non-small Cell Lung Carcinoma. Clinical Oncology, 2004, 16, 58-62.	1.4	4

#	ARTICLE	IF	CITATIONS
397	Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?. International Journal of Radiation Biology, 2004, 80, 499-506.	1.8	4
398	2387. International Journal of Radiation Oncology Biology Physics, 2006, 66, S425.	0.8	4
399	A Toast to the Silver Anniversary of Clinical Oncology: A Quarter of a Century of Advances in Evidence-based Radiation Dose Fractionation. Clinical Oncology, 2014, 26, 599-601.	1.4	4
400	In Regard to Vaidya etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 92, 954-955.	0.8	4
401	Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer. Radiotherapy and Oncology, 2019, 136, 9-14.	0.6	4
402	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE, 2021, 16, e0249123.	2.5	4
403	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. European Journal of Radiology, 2021, 139, 109668.	2.6	4
404	Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?. Journal of Clinical Oncology, 2021, 39, 3085-3086.	1.6	4
405	Lung Tumor Segmentation Using Electric Flow Lines for Graph Cuts. Lecture Notes in Computer Science, 2012, , 206-213.	1.3	4
406	Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes. Blood, 2019, 134, 3239-3239.	1.4	4
407	Remodelling of Trabecular Bone at the Proximal Tibia after Total Knee Replacement. A CT-Scan Study. Engineering in Medicine, 1986, 15, 89-93.	0.6	3
408	Introduction. Seminars in Radiation Oncology, 1994, 4, 53-54.	2.2	3
409	Chemotherapy and altered fractionation in head-and-neck cancer: in regard to Staar et al., IJROBP 2001;50:1161â€“1171. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1423.	0.8	3
410	155. International Journal of Radiation Oncology Biology Physics, 2006, 66, S87.	0.8	3
411	Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, S674-S675.	0.8	3
412	Hypofractionated Radiation Therapy for Prostate Cancer: More Food for Thought From Recent Trial. Journal of Clinical Oncology, 2014, 32, 1852-1853.	1.6	3
413	Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1608-1615.	1.1	3
414	Increasing utilization of regional nodal irradiation in elderly node-positive women and declining emphasis on demographic factors. Breast Cancer Research and Treatment, 2017, 165, 669-676.	2.5	3

#	ARTICLE	IF	CITATIONS
415	Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. Radiotherapy and Oncology, 2018, 128, 209-213.	0.6	3
416	Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria. BMC Cancer, 2020, 20, 98.	2.6	3
417	Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial. Neuro-Oncology, 2022, 24, 849-850.	1.2	3
418	Predictors of hormone response for patients with ER-unknown breast tumours. British Journal of Cancer, 1989, 59, 421-425.	6.4	2
419	3-Methoxyazetidinium chloride. Acta Crystallographica Section C: Crystal Structure Communications, 1993, 49, 932-934.	0.4	2
420	135. International Journal of Radiation Oncology Biology Physics, 2006, 66, S75-S76.	0.8	2
421	11â€ƒâ€ƒDesign of clinical trials in radiation oncology: saving lives, not grays. , 2007, , 196-211.		2
422	Dosimetric Evaluation of Helical IMRT, Traditional IMRT and 3-D Conformal Radiation for Inoperable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S632-S633.	0.8	2
423	Single Institution Experience Treating 100 Vestibular Schwannomas With Fractionated Stereotactic Radiation Therapy or Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2007, 69, S121.	0.8	2
424	In Response to Dr. Williams. International Journal of Radiation Oncology Biology Physics, 2011, 80, 639-640.	0.8	2
425	A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer: In Regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys) Tj ETQq1 1 0.784314 rgBT /Overlo		
426	Downstream Effect of a Proton Treatment Center on an Academic Medical Center. International Journal of Radiation Oncology Biology Physics, 2019, 104, 756-764.	0.8	2
427	Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis. Breast Cancer Research and Treatment, 2019, 175, 473-478.	2.5	2
428	Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDGâ€“PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. Diagnostics, 2020, 10, 1030.	2.6	2
429	In Regard to Thomson et al.. International Journal of Radiation Oncology Biology Physics, 2020, 107, 853-854.	0.8	2
430	Postoperative Treatment of Locally Advanced Head and Neck Cancers. , 2005, , 197-210.		2
431	Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy. International Journal of Particle Therapy, 2019, 5, 24-32.	1.8	2
432	Radiobiological Aspects of Brachytherapy in the Era of 3-Dimensional Imaging. , 2011, , 131-142.		2

#	ARTICLE	IF	CITATIONS
433	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 127-136.	1.0	2
434	Aspartate Î²-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target. Frontiers in Oncology, 2021, 11, 783744.	2.8	2
435	Small Cell Anaplastic Carcinoma of the Lung the Aarhus Experience 1976â€“1981. Acta Radiologica Oncology, 1984, 23, 153-158.	0.5	1
436	Hyperthermia in cancer treatment. Lancet, The, 1995, 345, 1635-1637.	13.7	1
437	The Influence of Delay in Diagnosis of Breast Cancer upon Outlook. Clinical Risk, 2000, 6, 4-6.	0.1	1
438	ICTR 2000: individualizing cancer treatment. International Journal of Radiation Oncology Biology Physics, 2001, 49, 299.	0.8	1
439	Evolution in H&N IMRT Practice and Early Assessment of Outcome at a Single Academic Center. International Journal of Radiation Oncology Biology Physics, 2005, 63, S360-S361.	0.8	1
440	O-146 Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Lung Cancer, 2005, 49, S50.	2.0	1
441	P-757 Omission of elective mediastinal node irradiation on basis ofCT-scans in patients with limited disease small cell lung cancer results in low isolated nodal failures: A phase II trial. Lung Cancer, 2005, 49, S318.	2.0	1
442	In response to Dr. PeÃ±agarÃ¢cano. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1274-1275.	0.8	1
443	A Prospective Study Comparing CT-Based to PET/CT-based Radiation Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2007, 69, S68-S69.	0.8	1
444	Pelvic Nodal Dose Escalation in Conjunction with Hypofractionated IMRT for High Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, S305.	0.8	1
445	Interim Results of a Phase I Risk-Stratified Dose Escalation Study using Hypofractionated Helical Tomotherapy for Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S107-S108.	0.8	1
446	Meta-analysis of the Î±/Î²-ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News or No News?. International Journal of Radiation Oncology Biology Physics, 2011, 81, S404.	0.8	1
447	In Regard to Vaidya et al. International Journal of Radiation Oncology Biology Physics, 2015, 92, 958-959.	0.8	1
448	Effect of reduction mammoplasty on acute radiation side effects and use of lumpectomy cavity boosts. Practical Radiation Oncology, 2017, 7, e299-e308.	2.1	1
449	Effect of PTV and Collimator Margins on Tumor Control for Patients with Stage III Non-small Cell Lung Cancer in NRG Oncology RTOG-0617. International Journal of Radiation Oncology Biology Physics, 2017, 99, S181-S182.	0.8	1
450	The Initial Clinical Experience of a Novel Breast Specific Stereotactic Radiosurgery Device. International Journal of Radiation Oncology Biology Physics, 2017, 99, E14-E15.	0.8	1

#	ARTICLE	IF	CITATIONS
451	Trends in Utilization of Hypofractionated Whole Breast Irradiation in Triple Negative Breast Cancer: A National Cancer Database Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, E43-E44.	0.8	1
452	Patient-Reported Outcomes (PROs) Comparing Pencil Beam Scanning (PBS) and Double Scatter/Uniform Scanning Proton Beam Therapy for Localized Prostate Cancer (PC): Analysis of PCG 001-09. International Journal of Radiation Oncology Biology Physics, 2018, 102, S34-S35.	0.8	1
453	Outcomes of a Community-based Breast Cancer Screening Program in Baltimore City. Journal of Health Care for the Poor and Underserved, 2018, 29, 898-913.	0.8	1
454	PV-0368 Persistence of late substantial patient reported symptoms (LAPERS): A report from the EMBRACE study. Radiotherapy and Oncology, 2019, 133, S183-S184.	0.6	1
455	Hypothyroidism (HT) after Radiotherapy (RT) in Children: Initial Results of Thyroid Gland Dose-Response Relationship from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative. International Journal of Radiation Oncology Biology Physics, 2019, 105, S81.	0.8	1
456	On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer. Acta OncolÃ³gica, 2019, 58, 390-392.	1.8	1
457	In Reply to Berk and Alfonso. International Journal of Radiation Oncology Biology Physics, 2020, 108, 834-835.	0.8	1
458	Metabolic heterogeneous zone assessed by ¹⁸FDGâ€PET is predictive of postablation mortality in patients with ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 2021, 32, 2238-2245.	1.7	1
459	Fractionation Effects in Clinical Practice. , 2010, , 40-54.		1
460	MOâ€Dâ€M100Jâ€08: Effect of a Biologicallyâ€Based Prescription Function in IMRT Dose Optimization. Medical Physics, 2007, 34, 2524-2524.	3.0	1
461	WE-E-BRA-03: Therapy Symposium: A ClinicianËˆs View of Quantec. Medical Physics, 2011, 38, 3815-3816.	3.0	1
462	Aspartate Beta-Hydroxylase (ASPH) As a Novel Therapeutic Target in Acute Myeloid Leukemia. Blood, 2018, 132, 5273-5273.	1.4	1
463	Dose escalation, treatment protraction, and the steepness of the dose-response curve for squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 1995, 34, 82-83.	0.6	0
464	Increased risk of recurrence for patients with EGFR and HER-p185 positive tumours; when treated adjuvantly with tamoxifen for one year. European Journal of Cancer, 1998, 34, S81.	2.8	0
465	Chemotherapy and accelerated radiotherapy in head and neck carcinoma: the experience from four swiss centres. European Journal of Cancer, 1999, 35, S168.	2.8	0
466	REPLY TO LETTER TO THE EDITOR, REGARDING OUR PAPER â€œINTERNATIONAL CONSENSUS ON PALLIATIVE RADIOTHERAPY ENDPOINTS FOR FUTURE CLINICAL TRIALS IN BONE METASTASESâ€• Radiotherapy and Oncology, 2003, 67, 252.	0.6	0
467	Molecular Markers in the CHART Trial. International Journal of Radiation Oncology Biology Physics, 2005, 63, S72.	0.8	0
468	International Survey of 4D Dose-Prescriptions in IMRT for Head and Neck Squamous Cell Carcinoma: A Modeled Comparison of Expected Outcome. International Journal of Radiation Oncology Biology Physics, 2005, 63, S75.	0.8	0

#	ARTICLE	IF	CITATIONS
469	Post-Radiotherapy Neck Dissection Following Comprehensive H&N IMRT. International Journal of Radiation Oncology Biology Physics, 2005, 63, S378-S379.	0.8	0
470	Combining H&N IMRT with Weekly Cisplatin Chemotherapy: Early Toxicity and Outcome. International Journal of Radiation Oncology Biology Physics, 2005, 63, S383.	0.8	0
471	Integral Radiation Dose to Normal Structures with Conformal External Beam Radiation. International Journal of Radiation Oncology Biology Physics, 2005, 63, S559.	0.8	0
472	Prognostic survival scores in patients referred for cardiac transplantation. Journal of Heart and Lung Transplantation, 2005, 24, S110.	0.6	0
473	Simplified prognostic models for the assessment of ambulatory heart failure. Journal of Heart and Lung Transplantation, 2005, 24, S119.	0.6	0
474	Dose and fractionation regimens for breast cancer â€“ Authors' reply. Lancet Oncology, The, 2006, 7, 619-620.	10.7	0
475	70 Theragnostic imaging for radiation oncology: Dose-painting by numbers. Radiotherapy and Oncology, 2006, 78, S24.	0.6	0
476	76 Novel biology, new technology, same ol' clinical practice?. Radiotherapy and Oncology, 2006, 78, S26-S27.	0.6	0
477	189 The response of head and neck tumours to radiotherapy may be influenced by the interaction between cell proliferation and vascularization. Radiotherapy and Oncology, 2006, 78, S65-S66.	0.6	0
478	80. International Journal of Radiation Oncology Biology Physics, 2006, 66, S47.	0.8	0
479	2396. International Journal of Radiation Oncology Biology Physics, 2006, 66, S429-S430.	0.8	0
480	Literature-based analysis of preoperative chemoradiotherapy in oesophageal cancer: In response to Srinivas et al.. Radiotherapy and Oncology, 2007, 82, 107-108.	0.6	0
481	Primary Histology is Associated with Volumetric Response Following Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases (BM). International Journal of Radiation Oncology Biology Physics, 2008, 72, S207.	0.8	0
482	Single Institution Experience Treating Medically Inoperable Stage I Endometrial Cancer with High-dose Rate Intracavitary Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, S370.	0.8	0
483	Estimating Life Years Lost to Quantify the Potential Benefit for Pediatric Patients of Advanced Photon or Proton Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S665.	0.8	0
484	Comparison of Methods to Analyze Pattern of Failure in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S540.	0.8	0
485	Equieffective dose and bioeffect modeling â€“ In reply to Dr. Fowler. Radiotherapy and Oncology, 2013, 108, 355.	0.6	0
486	In Reply to Arcangeli et al. International Journal of Radiation Oncology Biology Physics, 2013, 85, 898-899.	0.8	0

#	ARTICLE	IF	CITATIONS
487	Possession of the ATM Codon 1853 SNP is Associated With an Increased Risk for Radiation-Induced Toxicity. International Journal of Radiation Oncology Biology Physics, 2014, 90, S148-S149.	0.8	0
488	Temporal Stability and Reproducibility of FDG-PETâ€"Based Dose Painting Targets in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S514-S515.	0.8	0
489	Radiation Lumpectomy Boost and Acute Treatment Toxicities in Patients With or Without Reduction Mammoplasty as Part of Breast Conserving Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 93, E26.	0.8	0
490	In Reply to Boon et al. International Journal of Radiation Oncology Biology Physics, 2015, 91, 456-457.	0.8	0
491	Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2015, 93, E165-E166.	0.8	0
492	In Reply to Yamazaki etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 245-246.	0.8	0
493	Prognostic Value of 18-Fluorodeoxyglucose in Independent Training and Validation Sets of Patients With HNSCC Largely Explained by Association With Tumor Volume. International Journal of Radiation Oncology Biology Physics, 2016, 94, 921.	0.8	0
494	Patterns of Recurrence in Patients With Locally Advanced Non-Small Cell Lung Cancer (LANSCLC) Treated With Concurrent Chemoradiation (CRT) Followed by Surgery. International Journal of Radiation Oncology Biology Physics, 2016, 96, E452.	0.8	0
495	Multi-institutional Validation of a Novel Glioblastoma Prognostic Nomogram Incorporating MGMT Methylation. International Journal of Radiation Oncology Biology Physics, 2016, 96, S182.	0.8	0
496	Overall Survival After Endoscopic Surgery Versus Radiation as the Initial Treatment in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 94, 892-893.	0.8	0
497	(S001) Regional Nodal Irradiation in Elderly Node Positive Women: A Patterns of Care Study on Changes in Utilization Over a Decade. International Journal of Radiation Oncology Biology Physics, 2017, 98, E1.	0.8	0
498	Utilization of Hypofractionated Whole Breast Radiation Therapy in Patients Receiving Chemotherapy (2004-2013): A National Cancer Database Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, E394.	0.8	0
499	Dosimetric Comparison of Patient Alignment Techniques in Pencil Beam Scanning Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E714.	0.8	0
500	Lack of Consensus Guideline Driven Approach for Utilization of Accelerated Partial Breast Irradiation in the ASTRO â€œCautionaryâ€•Group: A National Cancer Database Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, E7-E8.	0.8	0
501	PV-0509: Failure type specific prognostic model for selection of HNSCC patients for experimental treatments. Radiotherapy and Oncology, 2017, 123, S268-S269.	0.6	0
502	The Downstream â€œHaloâ€•Effect of a Proton Therapy Center on an Academic Medical Center. International Journal of Radiation Oncology Biology Physics, 2018, 102, e427-e428.	0.8	0
503	Preliminary toxicity report comparing pencil beam scanning (PBS) to double scatter/uniform scanning proton beam therapy for localized prostate cancer (PC): Analysis of PCG 001-09. International Journal of Radiation Oncology Biology Physics, 2018, 102, S164-S165.	0.8	0
504	Editorial: Data Based Radiation Oncologyâ€"Design of Clinical Trials. Frontiers in Oncology, 2018, 8, 34.	2.8	0

#	ARTICLE	IF	CITATIONS
505	EP-1368 Circulating cell free DNA during chemoradiotherapy in non-small cell lung cancer patients. Radiotherapy and Oncology, 2019, 133, S747-S748.	0.6	0
506	In Reply to Tommasino etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 105, 677-678.	0.8	0
507	Brief Report: Herpes Simplex Virus Type-2 Shedding and Genital Ulcers During Early HIV in Zimbabwean Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 789-793.	2.1	0
508	MO-E-T-6E-02: Dose-Volume Modeling & Clinical Radiotherapy: The Art of Systematic Oversimplification. Medical Physics, 2005, 32, 2072-2072.	3.0	0
509	TH-E-M100J-05: Early Assessment of Radiotherapy Efficacy with FLT-PET Imaging. Medical Physics, 2007, 34, 2650-2650.	3.0	0
510	MOâ€Dâ€BRAâ€01: Hypofractionated RT: Biological Basis and Clinical Application in the Prostate and Lung. Medical Physics, 2007, 34, 2524-2525.	3.0	0
511	WE-D-AUD A-03: Control Theory to Manage Spatial and Temporal Physiologic Changes. Medical Physics, 2008, 35, 2943-2943.	3.0	0
512	SU-DD-A1-04: Impact of Prescription Dose Gradient Discretization On Dose Painting. Medical Physics, 2008, 35, 2631-2631.	3.0	0
513	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Physics in Medicine and Biology, 2009, 54, 1847-1847.	3.0	0
514	SU-FF-T-519: Potential for Increased Pneumonitis Risk with IMRT as Compared to 3D-CRT for Patients Receiving Adjuvant Chemotherapy: A Radiobiological Modeling Study. Medical Physics, 2009, 36, 2643-2643.	3.0	0
515	TH-D-304A-06: Comparison of Cu-ATSM and FMISO Uptake to Variations in Oxygen Tension. Medical Physics, 2009, 36, 2817-2817.	3.0	0
516	SU-FF-T-499: Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC): Limits and Recommendations for Use in Treatment Planning. Medical Physics, 2009, 36, 2638-2638.	3.0	0
517	MOâ€Dâ€204Bâ€01: Characterizing Uncertainties in Hypoxia Imagingâ€Based Dose Painting Prescriptions. Medical Physics, 2010, 37, 3341-3341.	3.0	0
518	Evidence-Based Head and Neck Oncology: Principles and Pitfalls. , 2011, , 317-325.		0
519	TU-A-BRC-04: Quantifying the Predictive Power of Multiparametric PET Imaging in a Prospective Veterinary Dose Escalation Trial through Voxel Regression. Medical Physics, 2011, 38, 3742-3742.	3.0	0
520	WE-E-BRA-02: Methodological Issues and Key Results in the QUANTEC 2010 Review of Radiation-Induced Normal Tissue Toxicity. Medical Physics, 2011, 38, 3815-3815.	3.0	0
521	MO-A-BRCD-01: Unsettled Issues in the Radiobiology of Emergent Technology: Hypofractionation and PET-Guided Treatment Planning. Medical Physics, 2012, 39, 3858-3858.	3.0	0
522	SU-E-T-167: QA of Dose-Painting Plans: Risk of Overdosage in the High-Dose Regions?. Medical Physics, 2013, 40, 242-242.	3.0	0

#	ARTICLE	IF	CITATIONS
523	TU-C-WAB-01: Accuracy Requirements and Uncertainty Considerations in Radiation Therapy. Medical Physics, 2013, 40, 433-433.	3.0	0
524	TH-A-WAB-11: A Novel Method to Determine Alpha/beta for Irradiated Normal Lung Tissue Using Computed Tomography Scans. Medical Physics, 2013, 40, 522-522.	3.0	0
525	Simulation of an HDR â€œBoostâ€•with Stereotactic Proton versus Photon Therapy in Prostate Cancer: A Dosimetric Feasibility Study. International Journal of Particle Therapy, 2021, 7, 11-23.	1.8	0
526	Incidence of rib fractures after stereotactic body radiotherapy for peripheral lung lesions: clinical experience and dose response estimation. Journal of Radiosurgery and SBRT, 2011, 1, 155-161.	0.2	0
527	Evaluating the Jaccard Similarity Index as a Persistence Measure of Multiple Anal Human Papillomavirus among Nigerian Men Who Have Sex with Men. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	1.7	0
528	Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer. International Journal of Particle Therapy, 2022, 8, 1-13.	1.8	0
529	Title is missing!. , 2020, 15, e0231884.		0
530	Title is missing!. , 2020, 15, e0231884.		0
531	Title is missing!. , 2020, 15, e0231884.		0
532	Title is missing!. , 2020, 15, e0231884.		0
533	Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clinical Cancer Informatics, 2022, , .	2.1	0